Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback